The purpose of this study were to find out the practical way to enlarged child-raising knowledge and to enhance their satisfaction with out-patient care by evaluating how effectively the education is done by nurses for mothers with ill-child and how their satisfaction with out-patient care changed. This study was designed as a Nonequivalent Control Group study. The subjects studied were consisted of the experimental and control group. Each consisted of 50 mothers with ill-child in pediatric department at one university hospital in Seoul. The period of this study is from May 20, 1996 to June 28, 1996. The first data were collected fro both of experimental and control groups in which mothers with ill-child come to the hospital for the first time. After this being done, the experimental group had been educated by the planned program and then the second data were collected from them. On the contrary, as for the control group, there had been no education and the second data were collected on the same method. The data analysis was done by SPSS program. The results of this study are as follow, 1. The child-raising knowledge level of mothers with education was higher than that of with no education.(t=18.84, df=49, p=0.000) 2. The satisfaction with out-patient care level of mothers with education was higher than that of no education.(t=10.51, df=49, p=0.000) Based on these results, I suggest as follow, 1. The research on the patients and their family should be made not only in pediatric department, but in every out-patient department. 2. For more effective education, it is required for all out-patient nurses to research the education demand of patients and their family. 3. To increase the effect of education, there must be the consultation room in out-patient department. 4. The meetings with the mothers with ill-child of the same illness have to be established and periodical education must be executed. 5. Audio-visual education programs like video tapes are needed to make use of waiting time for the medical treatment. 6. On-line consulting program are needed.
Education ; Humans ; Mothers* ; Outpatients* ; Seoul ; Statistics as Topic ; Child Health

No abstract available.
Ehlers-Danlos Syndrome*

Acantholytic acanthoma is a rare benign neoplasm of epidermal keratinocytes that clinically presents as a solitary, asymptomatic keratotic papule or nodule on the trunk. A 40-year-old female visited our hospital with a 20-year history of a single papule on her right thigh. On physical examination, the lesion measured 0.5×0.4 cm in size and appeared brown in color with central hyperkeratosis. Histopathological evaluation showed hyperkeratosis, acanthosis, papillomatosis, dyskeratosis, and acantholysis. Only six cases of acantholytic acanthoma have been reported in Korea. We report a rare case of acantholytic acanthoma that occurred in a 40-year-old female who presented with a keratotic papule on her right thigh.

Prurigo nodularis (PN) is a chronic cutaneous condition characterized by a papulonodular pruriginous eruption accompanied by pruritus. PN lesions are typically firm and itchy hyperkeratotic nodules and papules, which provoke a scratch response. PN may often represent an initial cutaneous manifestation of human immunodeficiency virus (HIV) infection. The association between PN and HIV is attributable to various etiopathogenetic mechanisms including cutaneous immunological abnormalities. Diagnosis of HIV infection in a patient with PN is challenging.We report a case of confirmed HIV infection in a patient with treatment-resistant PN, who was successfully treated using combination treatment that included HIV antiretroviral therapy and narrow-band ultraviolet-B radiation.

Sweet syndrome is characterized by fever, tender, erythematous skin lesions, neutrophilia, high levels of serum inflammatory markers, and diffuse mature neutrophil infiltration typically localized to the upper dermis. Various drugs have been shown to be associated with Sweet syndrome. Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma, has been reported to be associated with erythema, pruritus, eczemas, and, rarely, erythema multiforme-like skin changes or vasculitis. We describe a case involving a 65-year-old male who received bortezomib for the treatment of multiple myeloma. Over three cycles, multiple nodular lesions recurred through periods of aggravation and relief from symptoms. On the basis of the signs, symptoms, and biopsy results, the patient was diagnosed as showing Sweet syndrome. Skin lesions that occur during treatment of underlying disease can affect the patients’ treatment compliance. This case report indicates that a bortezomib rechallenge is an option for patients who develop sweet syndrome

Primary cutaneous anaplastic large cell lymphoma is primary cutaneous lymphoma that is composed of large lymphoid cells with anaplastic and pleomorphic morphology and expresses the CD30 antigen. Generally, primary cutaneous anaplastic large cell lymphoma is represented by a single, erosive plaque located on the trunk or extremities, but rarely on the dorsum of the hand. A 36-year-old man visited our hospital with a plaque on the dorsum of his left hand for 2 months. The plaque was 6×5 cm in size and violet-colored, with erosion. Histopathological findings showed infiltration of large anaplastic cells in the dermis and subcutaneous fat tissue. Immunohistochemically, it showed positive results for CD3, CD4, and CD30 and negativity anaplastic lymphoma kinase. Imaging examination showed no additional lesions, and the diagnosis was confirmed as primary cutaneous anaplastic large cell lymphoma. The patient was treated with radiation therapy four times and the lesion completely disappeared.

Acantholytic acanthoma is a rare benign neoplasm of epidermal keratinocytes that clinically presents as a solitary, asymptomatic keratotic papule or nodule on the trunk. A 40-year-old female visited our hospital with a 20-year history of a single papule on her right thigh. On physical examination, the lesion measured 0.5×0.4 cm in size and appeared brown in color with central hyperkeratosis. Histopathological evaluation showed hyperkeratosis, acanthosis, papillomatosis, dyskeratosis, and acantholysis. Only six cases of acantholytic acanthoma have been reported in Korea. We report a rare case of acantholytic acanthoma that occurred in a 40-year-old female who presented with a keratotic papule on her right thigh.

Prurigo nodularis (PN) is a chronic cutaneous condition characterized by a papulonodular pruriginous eruption accompanied by pruritus. PN lesions are typically firm and itchy hyperkeratotic nodules and papules, which provoke a scratch response. PN may often represent an initial cutaneous manifestation of human immunodeficiency virus (HIV) infection. The association between PN and HIV is attributable to various etiopathogenetic mechanisms including cutaneous immunological abnormalities. Diagnosis of HIV infection in a patient with PN is challenging.We report a case of confirmed HIV infection in a patient with treatment-resistant PN, who was successfully treated using combination treatment that included HIV antiretroviral therapy and narrow-band ultraviolet-B radiation.

Sweet syndrome is characterized by fever, tender, erythematous skin lesions, neutrophilia, high levels of serum inflammatory markers, and diffuse mature neutrophil infiltration typically localized to the upper dermis. Various drugs have been shown to be associated with Sweet syndrome. Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma, has been reported to be associated with erythema, pruritus, eczemas, and, rarely, erythema multiforme-like skin changes or vasculitis. We describe a case involving a 65-year-old male who received bortezomib for the treatment of multiple myeloma. Over three cycles, multiple nodular lesions recurred through periods of aggravation and relief from symptoms. On the basis of the signs, symptoms, and biopsy results, the patient was diagnosed as showing Sweet syndrome. Skin lesions that occur during treatment of underlying disease can affect the patients’ treatment compliance. This case report indicates that a bortezomib rechallenge is an option for patients who develop sweet syndrome